SANNZ Stock Overview
A specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Santhera Pharmaceuticals Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF9.33 |
| 52 Week High | CHF14.26 |
| 52 Week Low | CHF7.18 |
| Beta | 0.16 |
| 1 Month Change | -0.11% |
| 3 Month Change | -13.45% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -32.00% |
| Change since IPO | 342.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| SANNZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.3% | 1.0% | -1.2% |
| 1Y | n/a | -20.8% | 6.9% |
Return vs Industry: Insufficient data to determine how SANNZ performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how SANNZ performed against the UK Market.
Price Volatility
| SANNZ volatility | |
|---|---|
| SANNZ Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: SANNZ has not had significant price volatility in the past 3 months.
Volatility Over Time: SANNZ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 46 | Dario Eklund | www.santhera.com |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company’s lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies.
Santhera Pharmaceuticals Holding AG Fundamentals Summary
| SANNZ fundamental statistics | |
|---|---|
| Market cap | CHF105.95m |
| Earnings (TTM) | CHF54.78m |
| Revenue (TTM) | CHF103.38m |
1.9x
P/E Ratio1.0x
P/S RatioIs SANNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANNZ income statement (TTM) | |
|---|---|
| Revenue | CHF103.38m |
| Cost of Revenue | CHF3.24m |
| Gross Profit | CHF100.14m |
| Other Expenses | CHF45.36m |
| Earnings | CHF54.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 28, 2024
| Earnings per share (EPS) | 4.84 |
| Gross Margin | 96.87% |
| Net Profit Margin | 52.99% |
| Debt/Equity Ratio | 34.6% |
How did SANNZ perform over the long term?
See historical performance and comparison